Seeking Alpha


Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Amgen's (AMGN) blockbuster Enbrel drug for treating rheumatoid arthritis, which generated sales of $4.23B last year, is no more effective than a combination of three generic treatments, a study shows. While a regimen that includes Enbrel costs $25,000 a year per patient, the "triple therapy" costs just $1,000. The research didn't examine similar drugs from AbbVie (ABBV) or Johnson & Johnson (JNJ), although many doctors consider them to be equivalent to Enbrel. Despite the study, researchers feel that the branded treatments might be too well ensconced to be quickly replaced. [View news story]
    I do not believe this stub of an article. Enbrel not only took care of my daughters psoriatic arthritis systems it actually helped reverse the damage and after a couple of years she did not need the drug anymore. You would not have gotten this kind of performance from a generic cocktail that is designed to treat symptoms.
    Jun 12 06:46 AM | Likes Like |Link to Comment
1 Comment